Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lorlatinib

lorlatinib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of lorlatinib

8 trials tracked of lorlatinib: 2 in phase 3 or 4 and 1 with published results.

8Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 2 1 Phase 1 2 Other / NA 3
  1. Phase 4 Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer Completed
  2. Phase 4 Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India Completed
  3. Phase 2 A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China Completed
  4. Phase 1 NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Completed
  5. Phase 1 Lorlatinib Renal Impairment Study Completed
  6. N/A A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled Completed
Show 2 more trials
  1. N/A Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. Completed
  2. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
Pulmonology & Critical Care Sys. Review
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Frontiers May 16, 2026